Avidity Biosciences Inc (Nasdaq: RNA), a United States-based biopharmaceutical company, announced on Monday that it has named Tamar Thompson and Jean Kim as its new directors.

The new directors are replacing Todd Brady and Michael Martin.

Thompson has over twenty years of leadership experience in health care. Presently, she holds the position of the vice president, US Government Affairs and Policy for Alexion Pharmaceuticals Inc and as the chairman of the board of Alexion's Charitable Foundation. She has also served as head, federal executive branch strategy and state government affairs for Bristol-Myers Squibb Company, a strategic policy advisor and consultant for companies such as ADVI, Kimbell and Associates and Avalere Health.

Kim has more than twenty years of biotechnology experience and leadership on Wall Street. She has held the position of a partner at Deerfield Management Company LP. She is the founder a new gene therapy portfolio company at Deerfield Management. She has served as a healthcare investment professional for six years with Merrill Lynch Ventures and as a Financial Analyst in Merrill Lynch's investment banking department. She also serves on the Amplo Biotechnology board of directors.